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ABSTRACT
The objective of this paper was to evaluate the outcome of medical evacuation of first trimester miscarriages using 
dinoprostone. A prospective observational study in a tertiary centre between 1st January and 31st December 2018 in 
Obstetrics and Gynaecology unit, UKM Medical Centre. Women diagnosed with incomplete and missed miscarriage 
(n=41) at or less than 13 weeks of gestation were recruited. Dinoprostone 3 mg was inserted into the posterior fornix, 
twice within 6 h apart on day-1 followed by similar protocol on day-2. Patients were reassessed clinically and 
sonographically upon passing out products of conception, at 48 h and day-7. Complete evacuation was defined as closed 
cervical os and/or endometrial thickness of less than 15 mm sonographically. Treatment failure was defined as failure 
to achieve complete evacuation by day-7. Overall success rate was 55.3% (n=26) being better in incomplete (n=6, 
100%) as compared to missed miscarriage (n=21, 48.8%, p=0.03). Those with successful evacuation required 
dinosprostone at a mean of 8.4 ± 2.9 mg achieving complete miscarriage within a mean of 27.8 ± 16.6 h. Mean pain 
score was 5.8 ± 0.8 with mean patient satisfaction score of 8.7 ± 0.8. Mean drop in haemoglobin was 0.7 ± 0.2 g/dL. No 
major adverse effects were reported. Medical evacuation of miscarriage using intravaginal dinoprostone is safe and 
promising, with acceptable success rate and high patient satisfaction. This study supported previous studies suggesting 
presence of prostaglandin E2 receptors in the first trimester.
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ABSTRAK
Tujuan kajian ini dijalankan adalah untuk menilai hasil penggunaan ubat untuk rawatan keguguran pada trimester 
pertama. Ini adalah kajian prospektif yang dijalankan di unit Obstetrik dan Ginekologi, Pusat Perubatan UKM dari 1 
Januari hingga 31 Disember 2018. Semua pesakit (n=41) yang dikenal pasti mengalami keguguran pada atau kurang 
dari 13 minggu kandungan telah dimasukkan ke dalam kajian. Ubat dinoprostone 3 mg telah dimasukkan ke dalam faraj 
sebanyak 2 kali dalam beza masa selama 6 jam. Ini dilakukan selama 2 hari berturut-turut. Pesakit dinilai secara 
klinikal dan dengan menggunakan mesin imbasan jika ada perdarahan daripada faraj yang mengandungi tisu 
kandungan atau selepas 48 jam atau selepas 7 hari dari permulaan rawatan. Keguguran lengkap ditentukan apabila 
pintu rahim telah tertutup atau imbasan menunjukkan ketebalan dinding rahim kurang daripada 15 mm. Rawatan 
dianggap gagal jika keguguran lengkap tidak berlaku pada hari ketujuh selepas permulaan rawatan. Kejayaan 
keseluruhan adalah 55.3% (n=26) dan ia adalah lebih baik dalam kes pesakit yang telah keguguran tidak lengkap (n=6, 
100%) berbanding dengan mereka yang tiada langsung keguguran (n=21, 48.8%, p=0.03). Mereka yang telah berjaya 
memerlukan dinosprostone pada min 8.4 ± 2.9 mg dan kejayaan dicapai pada min masa 27.8 ± 16.6 jam. Min skor 
kesakitan adalah 5.8 ± 0.8 dan min kepuasan pesakit 8.7 ± 0.8. Min penurunan hemoglobin adalah 0.7 ± 0.2 g/dL. Tidak 
terdapat komplikasi yang teruk semasa kajian. Rawatan untuk keguguran dengan menggunakan ubat adalah selamat 
dan mempunyai kadar kejayaan yang baik. Kebanyakan pesakit juga berpuas hati. Ini membuktikan teori bahawa 
terdapat reseptor untuk prostaglandin E2 pada trimester pertama kandungan.
Kata kunci: Dinoprostone; evakuasi perubatan; keguguran trimester pertama
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Introduction
Spontaneous miscarriage is defined as pregnancy loss 
before viability, occurring in about 10% of all clinically 
recognised pregnancies (Wilcox et al. 1988). About 50% 
occurred in the first trimester due to genetic abnormalities 
(Eiben et al. 1990). Miscarriage can be classified as 
incomplete, complete, and missed. The diagnosis of 
intrauterine pregnancy must be confirmed via ultrasound 
examination and the subsequent management depends on 
the type of miscarriage. Both incomplete and missed 
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miscarriages require intervention to ensure complete 
evacuation of the product of conception (POC) in order to 
prevent further complications.
Different modalities in the management of these 
miscarriages are available. Each method namely expectant, 
surgical, and medical treatment has its own risks and 
benefits. Various published papers had looked into the 
superiority of a method to another. Conservative or 
expectant management may reduce the risks involved in 
surgical evacuation. However, it requires multiple follow-
ups with unpredictable achievement of complete 
miscarriage. On the other hand, surgical evacuation is a 
faster way of managing the problem definitively but is 
associated with risks of excessive curettage, uterine 
perforation, endometritis and incomplete evacuation 
(Nadarajah et al. 2014). 
Medical management is another safe option gaining 
more popularity. Its efficacy was comparable to the 
surgical evacuation and was preferred due to the safety 
profile (Nanda et al. 2012). The known drug that had been 
recognised for the licensed use in first trimester 
miscarriages was misoprostol, a prostaglandin E1 
synthetic analogue (WHO 2018). The success rate of 
achieving complete evacuation in incomplete miscarriages 
was comparable to surgical management (Kim et al. 
2017).
Since 2017, the Ministry of Health, Malaysia had 
stopped the use of misoprostol. Therefore, the aim of this 
study was to find a replacement for misoprostol to be used 
as a medical treatment for first trimester miscarriages in 
our local setting. This will allow the patients to have more 
than one option of treatment and avoid unwanted 
complications arising from surgical evacuation.
Materials and Methods
This was a prospective observational study from 1st January 
to 31st December 2018. Inclusion criteria were women with 
pregnancies of less than 14 weeks of gestation. Exclusion 
criteria were age less than 18 years old, inability to 
understand English or Malay, allergy to prostaglandin, 
factors necessitating immediate surgical evacuation such 
as excessive vaginal bleeding, haemodynamic instability 
and septic miscarriage, current use of anticoagulant, 
abnormal clotting profile, anaemia, suspected molar or 
ectopic pregnancy, pregnancy of unknown location (PUL) 
and high risk patients such as immunocompromised, 
haematological disorders, severe asthma and heart disease. 
Ethics approval was obtained from the local ethics 
committee (FF-2018-189).
All suitable patients were assessed in the patient 
admission centre (PAC). Complete history, physical 
examination and ultrasound were performed. Intrauterine 
pregnancy was confirmed via ultrasound examination 
finding of an intrauterine gestational sac. The gestational 
age was determined based on the last menstrual period or 
a dating scan. 
Incomplete miscarriage was diagnosed based on 
opened cervical os and endometrial thickness (ET) of 15 
mm or more. The ultrasound criteria for missed miscarriage 
were (Doubilet et al. 2014) mean gestational sac diameter 
of > 25 mm without a measurable embryonic pole, an 
embryo with crown rump length of  > 7 mm without cardiac 
activity, absence of embryo with heartbeat 2 weeks or more 
after a scan that showed a gestational sac without a yolk 
sac and absence of embryo with heartbeat 11 days or more 
after a scan that showed a gestational sac with a yolk sac.
Full blood count was taken prior to treatment and 
repeated at the end of the protocol. Dinoprostone 3 mg was 
inserted twice into the posterior fornix, 6 h apart within 24 
h. The next day similar protocol was followed. Parameters 
that were documented during treatment period were blood 
pressure, pulse rate and temperature, pain score using visual 
analogue scale, analgesia required (paracetamol 1 g), side 
effects, treatment administered, number of dinoprostone 
used, achievement of complete miscarriage and change in 
the haemoglobin level. The end of the protocol was 
achieved either within 48 h of admission or after 7 days 
from the initiation of treatment.
Patients who passed out POC were assessed clinically 
and transvaginal ultrasound performed. Complete 
evacuation was diagnosed when the cervical os was close 
on vaginal examination and transvaginal ultrasound 
showed ET of less than 15 mm. POC was collected and sent 
for histopathological examination (HPE). After 48 h of 
treatment protocol, patients who did not pass out any POC 
without any excessive vaginal bleeding or side effects were 
allowed home. Once the POC was passed out or if they 
developed excessive vaginal bleeding, they were advised 
to return to the PAC immediately. They were also counseled 
to document the date and time of passing out POC.
If there was no progress at home, the patients were 
reviewed after 7 days in the gynaecology clinic and 
haemoglobin level was repeated along with vaginal 
examination and ultrasound. If there was still retained POC, 
patients were subjected to surgical evacuation. In the event 
of excessive vaginal bleeding, foul smelling discharge or 
fever, or if the patient refused to continue, surgical 
evacuation was carried out at any point of time. Treatment 
failure was defined as failure in achieving complete 
evacuation after 7 days. The contact number of the main 
researcher and PAC were provided.
The sample size of this study was calculated using an 
online sample size calculator available at www.sample-
size.net/sample-size-conf-interval-proportion/ using the 
formula for sample size assessment for a descriptive study 
of a dichotomous variable. The sample size was determined 
based on 95% confidence interval with a total confidence 
interval (CI) width of 0.2, assuming 60% rate of complete 
miscarriage after medical treatment.
Data entry and analysis were performed using SPSS 
Statistics Version 23. All outcome measures were 
analysed using Chi Square, Fisher Exact and Students 
t-test. Difference between two groups was expressed as 
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TABLE 1. Demographic data and baseline clinical  characteristics of study population (n=47)
Mean age, years ± SD (range) 33.9 ± 4.9 (25 - 45)
Mean Body Mass Index, kg/m2 ± SD (range) 27.7 ± 5.5 (16.3 – 44)
Mean gestational age at diagnosis, weeks ± SD (range) 10.4 ± 1.6 (6.4 - 12.6)
Parity, n (%) 
Nulliparous
Multiparous
11 (23.4)
36 (76.6)
Type of miscarriage, n (%)
Missed
Incomplete
41 (74.5)
6 (25.5)
Previous miscarriage, n (%)
Yes
No
14 (29.8)
33 (70.2)
Vaginal bleeding, n (%)
Yes
No
35 (74.5)
12 (25.5)
Abdominal pain, n (%)
Yes
No
24 (51.1)
23 (48.9)
Treatment outcome, n (%)
Successful
Failed
26 (55.3)
21 (44.7)
odds ratio (OR) or mean difference (ß)(95% Confidence 
Interval). P value of less than 0.05 was considered 
statistically significant.
Results and Discussion
There were 59 women recruited but 8 of them did not 
complete the protocol, leaving 47 women with missed 
(n=41) and incomplete (n=6) miscarriages. All participants 
were Malay with majority of them multiparous and 
diagnosed with missed miscarriage (Table 1). Their main 
presentations were abdominal pain and vaginal bleeding 
at mean gestational age of 10.4 ± 1.6 weeks. Twenty-six 
(55.3%) had successful medical evacuation, at a mean 
gestational age of 10 ± 1.8 weeks. Successful evacuation 
was achieved in 55.3% of women.
Table 2 shows the demographic data and baseline 
characteristics of patients based on the treatment outcome. 
TABLE 2. Demographic and baseline clinical characteristics of study population by treatment outcome (n=47)
Successful 
26 (55.3%)
Failed
21 (44.7%)
OR/ß (95% CI)
p-value
Mean age, years ± SD (range) 34.8 ± 4.8 
(25 – 45)
32.9 ± 4.9 
(25 – 45)
1.8 (-1.0 - 4.7)
0.2**
Mean Body Mass Index, kg/m2 ± SD (range) 27.2 ± 5.7 
(16.3 – 44.0)
28.1 ± 5.4
(19.8 - 43.0)
-1.0 (-4.2 – 2.3)
0.6
Mean gestational age at diagnosis, weeks ± SD (range) 10.0 ± 1.8 
(6.4 – 12.6)
10.7 ± 1.1 
(8.6 - 12.4)
-0.7 (-1.6 - 0.2)
0.13**
Type of miscarriage, n (%)
Missed
Incomplete
20 (76.9)
6 (23.1)
21 (100)
0
0.5 (0.4 - 0.7)
0.03*
Parity, n (%)
Nulliparous
Multiparous
7 (26.9)
19 (73.1)
4 (19)
17 (81)
1.6 (0.4 - 6.3)
0.7*
Mean drop in haemoglobin level, g/dL ± SD (range) 0.6 ± 0.3 
(0 - 1.1)
0.3 ± 0.2 
(0 – 0.8)
0.3 (0.1 - 0.4)
<0.001
Mean patient satisfaction score ± SD, (range) 8.5 ± 1.0 
(6 - 10)
3.0 ± 1.1 
(1 - 5)
5.5 (4.9 - 6.2)
<0.001
*data analysed using Fisher exact test, **data analysed using Student t-test 
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TABLE 4. A subgroup analysis of demographic data, clinical characteristics and detail of treatment in patients with successful 
evacuation by type of miscarriage (n=26)
Missed
20 (76.9%)
Incomplete
6 (23.1%)
OR/ß (95% CI)
p value
Mean age, years ± SD (range) 35.0 ± 4.9 
(25 – 45)
34.3± 3.9
(28 – 41)
0.6 (-4.1-5.3)
0.8**
Mean Body Mass Index, kg/m2 ± SD (range) 26.4 ± 6.2
(16.3 – 44.0)
30.0 ± 2.2
(27.5 – 32.6)
-3.6 (-9.0-1.8) 
0.2**
Mean gestational age at diagnosis, weeks ± SD (range) 10.1 ± 1.8 
(7.4 - 12.4)
10.0 ± 2.2
(6.4 – 12.6)
0.1 (-1.6 – 1.9)
0.9**
Parity, n (%)
Nulliparous
Multiparous
3 (42.9)
17 (89.5)
4 (66.7)
2 (33.3)
0.08 (0.01 - 0.7)
0.03*
Mean pain score, mm ± SD (range) 1.2 ± 1.5
(0 – 6)
3.8 ± 1.0
(3 – 5)
-2.1 [-3.8 - (-0.5)]
0.01*
Mean duration from first dinoprostone insertion to evacuation, hours ± SD 
(range)
33.3 ± 36.6
(2.5 – 131.0)
27.8 ± 16.6 
(9 – 48)
5.4 (26.7 - 37.5)
0.7
Mean dose of dinoprostone required, mg ± SD, (range) 8.1 ± 3.8 
(3 – 12)
8.5 ± 2.9
(6 - 12)
-0.4 (-3.9 - 3.1)
0.8
Mean drop in haemoglobin level, g/dL ± SD (range) 0.6 ± 0.3
(0.0 – 1.1)
0.7 ± 0.2
(0.3 – 0.9)
-0.1 (-0.3 - 0.2)
0.6
Mean patient satisfaction score ± SD, (range) 8.5 ± 1.1 
(6 – 10)
8.7 ± 0.8 
(8 – 10)
-0.2 (-1.1 - 0.8)
0.7
*data analysed using Fisher exact test, **data analysed using Student t-test
There were significantly more patients with missed 
miscarriage who had failed medical treatment with 
dinoprostone as compare to incomplete miscarriage 
(p=0.03), more significant drop in haemoglobin levels in 
patients with successful treatment (p<0.001) and higher 
patients’ satisfaction in the group who succeeded (p<0.001). 
There was no difference between the two groups in regards 
to age, body mass index, parity and gestational age. 
The success rate with dinoprostone was 55.3% with 
100% success rate for incomplete and 48.8% for missed 
miscarriage (data not shown). Table 3 demonstrated the 
clinical characteristics and detail of treatment based on the 
type of miscarriage. The patients with incomplete 
miscarriage experienced significantly more abdominal pain 
(p=0.03) but higher satisfaction rate (p=0.001). There was 
no significant difference in the mean duration from 
initiation of treatment to achievement of complete 
evacuation, mean dose of dinoprostone required and mean 
drop in haemoglobin levels.
Table 4 shows the demographic data, clinical 
characteristics and detail of treatment in patients who had 
successful evacuation. There were significantly more 
multiparous women in the missed miscarriage group 
(p=0.03) and more women with incomplete miscarriage 
experienced higher pain score (p=0.01). Both groups were 
similar in regards to the mean age, mean body mass index, 
mean gestational age, duration from commencement of 
treatment to complete evacuation, mean dose of 
TABLE 3. Clinical characteristics and detail of treatment in study population by type of miscarriage (n=47)
Missed
41 (87.2%)
Incomplete
6(12.8%)
OR/ß (95% CI)
p-value
Mean duration from first dinoprostone insertion to evacuation, hours ± 
SD (range)
33.3 ± 36.6
(2.5 - 131)
27.8 ± 16.6 
(9 - 48)
5.4 (-26.6 - 37.5)
0.73
Mean dose of dinoprostone required, mg ± SD, (range) 10.2 ± 3.3
(3 - 12)
8.4 ± 2.9
(6 - 12)
1.6 (-1.3 - 4.4)
0.26
Mean pain score ± SD, (range) 4.0 ± 1.9
(0 - 8)
5.8 ± 0.8
(5 -7)
-1.8 [-3.4 - (-0.2)]
0.03
Mean drop in haemoglobin level, g/dL ± SD (range) 0.4 ± 0.3
(0 – 1.1)
0.7 ± 0.2 
(0.3 – 0.9)
-0.2 (-0.4 - 0.04)
0.1
Mean patient satisfaction score ± SD, (range) 5.7 ± 3.0 
(1 - 10)
8.7 ± 0.8 
(8 - 10)
-1.8 [-2.7 - (-0.9)]
0.001
data analysed using Fisher exact test
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dinoprostone required, mean drop in haemoglobin levels 
and satisfaction score. 
Discussion
Medical management of miscarriage is an option gaining 
popularity with high efficacy and patient acceptability. The 
Ministry of Health Malaysia has approved the off-label use 
of misoprostol for treatment of first trimester miscarriage 
in 2011. Recently the privilege for off-label use of 
misoprostol was revoked and the import of the drug was 
stopped. This was due to the several reported cases with 
adverse side effects in patients who received misoprostol 
for induction of labour in the third trimester. Hence, 
medical management of patient with first trimester 
miscarriage is currently limited to surgical evacuation only. 
Although gemeprost is an available option with 76.7% 
success rate in missed miscarriage, the price is expensive 
in our centre (Egarter et al. 1995).
To date, published data on the use of prostaglandin E2 
in first trimester miscarriages is limited. Wagner et al. 
(2011) had investigated the use of misoprostol, gemeprost 
and dinoprostone for termination of pregnancy between 
11 and 24 weeks’ gestation for fetal anomalies.  Eleven 
women had gone through the dinoprostone gel protocol of 
0.5 mg 4 to 6 hourly till adequate contractions were 
achieved. Overall, the reported success of fetal expulsion 
24 h after first induction was 90% but it was not mentioned 
in detail of which agent was the main contributor.
Al Inizi and Ezimokhai (2003) had published the only 
paper that compared misoprostol and dinoprostone in a 
prospective randomised study for the management of 
missed miscarriage. Dinoprostone 3 mg tablets were 
inserted vaginally 6 h apart for a maximum dose of 36 mg 
over 6 days. The success rate was 24.2% and the use of 
dinoprostone was associated with significantly more 
surgical evacuation and longer hospital stay. However, 
there was no difference in requirement for analgesia and 
drop in the haemoglobin levels. In contrast, our study had 
shown higher success rate for missed miscarriage i.e. 
55.3% as compared to misoprostol which was reported to 
have higher success rate of 76.7% (Egarter et al. 1995). 
Despite the lower success rate in our study, this result was 
still promising. 
To the best of our knowledge, this was the first study 
that had used dinoprostone 3 mg tablet for medical 
treatment in women with incomplete miscarriages in 
Malaysia. Although the number of women was small but 
the success rate was 100%. This is comparable to the use 
of misoprostol in incomplete miscarriage with reported 
success rate of 92.7% and 92.9% (Egarter et al. 1995; Ng 
et al. 2015; Ngoc et al. 2013). However, none of the patients 
with either successful or failed evacuation had excessive 
bleeding, developed infection or required emergency 
surgical evacuation. Among those who had failed treatment 
and required surgical evacuation, no complications from 
the procedure were reported. This was most likely due to 
the cervical ripening effect prior to procedure, which had 
been demonstrated in previous studies (MacKenzie 1981; 
Sparrow et al. 1998). No side effect of dinoprostone was 
reported in this study. Only one patient required analgesia 
due to excessive abdominal cramps with pain score of 8 
and as expected, the mean patient satisfaction score was 
higher in those who had successful evacuation.
The results of this study support findings from earlier 
studies on the use of PGE2 analogue in the first trimester. 
The cervix produces prostaglandin in early pregnancy and 
the concentration increases with gestational age (Ellwood 
et al. 1980). It has been proven that cervical ripening in 
the first trimester prior to surgical evacuation was beneficial 
in reducing the cervical resistance during dilatation and 
hence reduced complications namely uterine perforation. 
The side effects were minimal with 5 mg as compared to 
10 mg which was in agreement with the results of our study 
(Anthony et al. 1984; MacKenzie 1981). This is highly 
suggestive of the presence of prostaglandin E2 receptors 
in the first trimester.
Limitation of this study was it is an observational 
study. However, based on the findings we obtained general 
overview on efficacy as well as its safety profile. This will 
become our basis as to how we are going to move forward 
for future research. Apart from that, our sample size was 
small with all participants were Malay. We hoped to recruit 
other ethnicity as well in our future study. This will be 
more representative of Malaysian population. Our 
population sample was limited to Asian ethnicity, which 
cannot be extrapolated to women in other ethnic origin. 
Randomised clinical trial using higher dose comparing 
dinoprostone with other agents should be conducted in the 
future.
The use of prostaglandin E2 for medical evacuation of 
miscarriage is promising with successful evacuation rate 
of 56.5% and high patient satisfaction. Additionally, in 
those who failed medical evacuation still benefit from the 
cervical ripening prior to surgical evacuation which avoids 
the associated complications. Similar studies involving 
larger population size are recommended. Randomised 
controlled trial between dinoprostone and other pre-
existing agents used for medical termination such as 
misoprostol or gemeprost will be beneficial. 
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